Abstract
Introduction
Human hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with an annual incidence rate of about 600,000 cases, among whom 55% are in China [1] . HCC is characterized by vascular invasion, rapid progression and poor prognosis. The 5-year overall survival rate of individuals with HCC is only 8.9% , and this has barely improved over the past two decades [2] . New prognostic markers are needed to help identify patients who are likely to have a poor prognosis and benefit from more aggressive treatment approaches. [3] . Several [4] , basigin [5] , HAb18G [6] and M6 antigen [7] . Earlier studies demonstrated that CD147 molecule is highly expressed on the surface of various cancer cells, including cancers of liver, lung, breast, kidney, colon, prostate and oesophagus [8] . There is emerging evidence indicating that increased CD147 expression significantly contributes to tumour progression by inducing the expression of matrix metalloproteinases (MMPs; mainly MMP-2 and MMP-9) [9] [10] [11] and vascular endothelial growth factor [12] , activating the urokinase-type plasminogen activator system, conferring the resistance of tumour cells to anoikis and thus promoting tumour invasion and metastasis [13, 14] . Additionally, CD147 overexpression in tumour cells was significantly associated with a poor prognosis [15, 16] . Nonetheless, although CD147 plays a critical role in tumour progression and prognosis, the mechanisms underlying the up-regulation of this molecule in cancer cells remain largely unknown. [17] [18] [19] . Hypermethylation of normally unmethylated tumour suppressor genes and hypomethylation of normally methylated proto-oncogenes have been identified as crucial events in the process of carcinogenesis [20] . Furthermore, altered DNA methylation patterns of these genes have been reported to be significantly correlated with tumour differentiation, progression and prognosis [21] . Although altered methylation of a series of genes has been to date identified in human cancers, whether the methylation status influence the CD147 expression has not yet to be elucidated.
CD147 is a transmembrane protein with highly glycosylated modifications. It contains two extracellular immunoglobulin domains (C2 and V sets), exhibiting the characteristics of the immunoglobulin superfamily members

Recently, DNA methylation at CpG dinucleotides has been well documented as a common mechanism for regulation of gene expression in mammalian cells. A series of studies demonstrated that aberrant methylation (hypermethylation and hypomethylation) is one of the most consistent epigenetic hallmarks of human cancer
The most well-defined mechanism involved in the regulation of methylation-mediated gene expression is the direct binding blocking of transcription factors to their CpG-containing binding sites [22] . Sp1 is a well-characterized sequence-specific transcriptional factor that regulates a large number of house-keeping and tissue-specific genes by binding to GC-rich DNA sequences in the promoter region of many human genes [23, 24] . Numerous previous studies have shown that methylation status of the Sp1 consensus binding site influences the Sp1 binding and thus regulates the gene transcription [25, 26] . It has been convincingly reported that CpG islands and potential binding sites of Sp1 exist in the promoter region of CD147 [27, 28] 
Materials and methods
Cell culture and tissues collection
The following cell lines were used in this study: human normal liver cell QZG [29] , QSG-7701 [30] and HL-7702 [31] [32] . The sequences of all PCR primers were listed in Table 1 . 
Sodium bisulphite genomic sequencing (BGS)
Genomic
Sp1 transfection and knockdown
Sp1 eukaryotic expression vector and small interfering RNAs designed to knockdown Sp1 [36] were transfected into HepG2 cells using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions, respectively. Sp1 siRNA duplex at a final concentration of 0.2 M was transfected into 40% confluent cells, which were harvested 36-44 hrs after transfection.
5-Aza-2-deoxycytidine treatment
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared from HepG2 cells as previously described [37] . 
Methylation-specific PCR (MSP) analysis
Immunohistochemical staining
CD147 expressions in HCC tissue specimens were detected by immunohistochemical staining as described previously [8, 33] 
Induction of CD147 gene expression by 5-Aza-dC
To verify the role of DNA methylation in CD147 expression regulation, the QZG cell was treated with DNA-demethylating reagent 5-Aza-dC and then CD147 expression was examined. The mRNA and protein expression of CD147 were significantly increased in a dose-dependent manner after treatment (Fig. 4A-C) (Fig. 4A-C) . (Fig. 4D) . These findings suggested that methylation of CpG sites in the CD147 promoter interfered with the binding of Sp1. The results in Figure 4 indicate that 5-Aza-dCinduced CD147 up-regulation is mostly due to the demethylation of CD147 promoter region through increasing Sp1 binding rather than the increased Sp1 expression.
Demethylation increased the binding of Sp1 to the CD147 promoter in vivo
Fig. 2 DNA Methylation profile of the CpG island at the CD147 promoter region. (A) Map of predicted CpG islands. One CpG island located at Ϫ340 to ϩ37 was identified in CD147 promoter (ϩ1, transcriptional start site; ATG, translational starting site). GC percentage and observed/expected CpG were calculated using the CPGPLOT program. (B) Schematic representation of CpG island. The 46 CG dinucleotides were denoted as grey shadow. CpG sites were numbered from 1 to 46 relative to the transcription start site (ϩ1 indicated with an arrow). Underlined region indicated Sp1 binding sites. (C)
Sequences of the CD147 promoter region after bisulphite modification were analysed in normal and cancer cell lines. Black circle, methylated cytosine; white circle, unmethylated cytosine in the dinucleotide CpG.
Fig. 3 The involvement of Sp1 in regulating CD147 expression. (A) Analysis for transcription activity of CD147 promoter and the regulation role of Sp1 in HEK-293 cell by the co-transfection of luciferase reporter plasmid (CD147P/ pGL3 or pGL3-Basic) and expression vector (pcDNA3.1 or Sp1/pcDNA3.1). Transfected cells were either untreated or treated with increasing concentration (0.5, 1, 5 M) of mithramycin A. The luciferase activity value of each sample was first normalized for transfection efficiency by cotransfection with the pRL-TK plasmid. The transcriptional activity of promoter construct was shown as the luciferase activity relative to that of the pGL3-Basic vector (a promoter-less vector) and shown as the mean Ϯ S.D. for three independent experiments. *P Ͻ 0.05. (B) The involvement of Sp1 in regulating CD147 expression. HepG2 cell was transfected with siRNA targeting Sp1 and Sp1 expression vector, respectively. Upper panel, regular RT-PCR. Lower panel, real-time quantitative RT-PCR. Control siRNA was used as negative control.
Methylation status interfered the Sp1 binding to the CD147 gene promoter and inhibited CD147 transcriptional activity in vitro
To directly examine if Sp1 binds to the putative binding site within the critical CD147 promoter region, EMSA was performed with biotin-labelled oligonucleotides spanning the Sp1-binding sites as probe. Shifted complexes were observed when the labelled wild-type probe was used (Fig. 5A, lane 2) , while these complexes disappeared when 100-fold molar excess of unlabelled wild-type probe was added (Fig. 5A, lane 3) . EMSA was also performed by using mutant probes in order to understand the contribution of the Sp1-binding sites to the observed binding patterns. The mutation in the Sp1-binding sites dramatically decreased the level of complex formation (Fig. 5A, (Fig. 5A, lane 6) . However, no supershift was observed when control IgG was used (Fig. 5A, lane 5) . We also observed that Sp1 could not bind to the methylated CD147 gene promoter probe (Fig. 5A, lane 7) . The EMSA results demonstrated that Sp1 specifically bound to the Sp1-binding sites in the CD147 gene promoter and this binding could be interfered by methylation status.
lanes 4). To further confirm the specific binding of Sp1 to the CD147 minimal promoter, supershift assay was performed with anti-Sp1 antibody. The protein-DNA complex of interest was supershifted by anti-Sp1 antibody
We then analysed the effect of in vitro DNA methylation on the CD147 promoter activity through transfecting HEK-293 cells with methylated CpG reporter constructs (Fig. 5B). Our results demonstrated that there was no obvious CD147 promoter activity in HEK-293 cells co-transfected with the metCD147P/pGL3 and an empty expression vector pcDNA3.1 or metCD147P/pGL3 and Sp1/pcDNA3.1, whereas high relative luciferase activity was observed in HEK-293 cells transfected with unmethylated CD147P/pGL3 vector (P Ͻ 0.05). These results suggest that Sp1-mediated transcriptional activation of CD147 promoter is inhibited by CpG methylation. The results of Figure 3 indicated that promoter hypomethylation up-regulated CD147 expression through increasing Sp1 binding.
Methylation analysis of CD147 promoter in HCC and ANT tissues
BGS was carried out to investigate the methylation level of CD147 promoter in 54 pairs of HCC and ANT tissues. The percentage of methylated CpG sites in all sequenced
CpG sites was used to represent the methylation level for each sample as previously described [38] . The representative data from 10 paired tissues were shown in Figure 6A . Our Figure 6C . Correlation analysis indicated that there was a significant inverse correlation between the CD147 expression level (denoted as total score of immunohistochemistry) and promoter methylation with a correlation coefficient (r) ϭ Ϫ0.615 and R 2 linear ϭ 0.378 (Fig. 6D) . 
Hypomethylation of CD147 gene was associated with poor prognosis in HCC patients
Associations of CD147 promoter methylation with clinicopathological characters were analysed in 54 HCC patients ( (Fig. 7A) , and that HCC patients with methylated CD147 promoter had significantly longer median survival duration than patients with unmethylated CD147 promoter (12 months versus 7.0 months, P ϭ 0.023, log-rank test) (Fig. 7B) . These results indicated that hypomethylation of CD147 gene was associated with poor prognosis in HCC patients.
Fig. 6 Analysis of methylation status in CD147 promoter and CD147 expression level in HCC and ANT tissues. (A) Representative methylation profiles of CpG island in CD147 promoter in HCC and ANT tissues detected by BGS. Open and closed circles indicate unmethylated and methylated CpG sites, respectively. The percentage of methylated CpG sites in all sequenced CpG sites is shown in parentheses. (B) Representative results of MS-PCR analysis in HCC tumour tissues (T) and ANT tissues (N). M: methylation; U: unmethylation. (C) Immunohistochemical staining analysis for CD147 expression in HCC tis
Discussion
In our study, we evaluated the effect of methylation status of CD147 promoter on CD147 expression and the possible functional mechanism. Our results demonstrated that the hypomethylation of CD147 promoter significantly up-regulated CD147 expression by increasing the Sp1 binding. In addition, we also observed that low methylation of CD147 promoter was significantly associated with poor prognosis in HCC patients.
A series of previous reports demonstrated that CD147 is overexpressed in various malignant tumour cells and involved in tumour progression [39, 40] [6, 8] . However, to date, there has been no report to elucidate the mechanism underlying the transcriptional upregulation of CD147.
Many reports have emphasized that epigenetic modifications play crucial roles in the transcriptional regulation of gene expression [21] . Previous analyses showed that promoter region of CD147 gene contains CpG islands that have numerous potential DNA methylation sites (CpG motifs) [27, 28] [44] . The hypomethylation and overexpression of proto-oncogenes c-myc and c-jun have been found in chemically induced tumours in mouse liver [45] . Additionally, the correlation of hypomethylation and overexpression of MAGE-A1, MAGE-A3, insulin-like growth factor (IGF )-II and trefoil factor (TFF )3 genes were also clearly observed in human HCC tissues [46] [47] [48] [50, 51] . CD147 is highly expressed on the HCC and the expression level is significantly associated with the serum AFP level [52, 53] 
